June 01, 2025
Article
Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.
December 13, 2024
Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.
Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.
December 10, 2024
A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.
Anemia Management in Myelofibrosis: Survival and Quality of Life
Simple Ways for Patients With Cancer to Start Exercising
Finding Credible Voices in the Lynch Syndrome Community
Understanding Your Stage 2 Lymphoma Diagnosis